newsfilter
← Latest News
GlobeNewswire·

Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Essential Thrombocythemia at EHA 2022

- The study completed enrollment with 73 patients in April 2022 - - As of the data cutoff of 29 April 2022, bomedemstat demonstrated durability of response with 81% of patients achieving normalized platelet counts for at least 12 weeks - - 58% of p